Contineum Therapeutics CTNM Cash Flow Statement (2023-2026)

NASDAQ CTNM
$8.56 +0.10 (+1.18%)
As of: Oct 21, 2026 · 1:19 PM EDT
Reported Financials

Contineum Therapeutics Quarterly Cash Flow Statement

Periods 14 quarters
Latest Jun 2026

Contineum Therapeutics reported cash from operations of -$11.50M and free cash flow of -$11.51M for the quarter ended Jun 2026, up 26.6% year over year. This cash flow statement covers 14 quarters of results from Mar 2023 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow StatementCash Flow Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income -4.82M41.56M-6.25M-7.77M-8.42M-9.01M-10.27M-14.57M-15.99M-16.04M-12.80M-15.18M-14.46M-15.20M
Depreciation, Depletion & Amortization
Amortization of Deferred ChargesAmort. Deferred Charges 0.03M-0.22M0.00M
Depreciation & Amortization (CF)Dep. & Amort. 0.07M0.04M0.04M0.04M0.06M0.06M0.06M0.12M0.08M0.08M0.08M0.09M0.08M0.13M
Share-based CompensationStock Comp. 0.49M0.49M0.48M0.76M0.77M1.49M2.29M2.25M2.57M0.27M2.57M2.48M3.82M3.84M
Gains from Sales and DivestituresGains Divest 0.02M-0.07M0.00M
Gains from Investment SecuritiesGains Investment -0.02M0.00M0.00M0.01M0.00M0.00M0.01M
Other non-cash itemsOther Non-Cash -0.02M0.00M-0.94M-0.66M-0.01M-0.91M-0.05M0.28M0.23M-0.33M
Change in Working Capital
Change in Account PayablesChange Payables 0.28M-0.31M0.66M-0.63M-0.07M0.17M0.66M0.38M1.83M-1.64M-1.22M0.16M0.49M-0.99M
Change in Accured ExpensesChange Accured Exp. -0.98M2.15M2.02M-1.61M-0.38M-1.46M1.21M2.94M-2.86M-0.10M0.35M2.10M-3.53M0.77M
Change in Other Operating AssetsOther Assets Change 0.06M-0.08M1.30M-0.01M-0.71M-1.07M-0.44M0.39M-0.20M-0.06M1.17M2.50M1.62M-0.61M
Change in Other Operating LiabilitiesOther Liabilities Change -0.26M-0.25M-0.26M-0.57M0.01M0.01M0.01M0.03M-0.26M-0.25M-0.26M-0.50M-1.30M-0.38M
Other Working Capital ChangesOther WC Changes -0.32M-0.18M-1.56M-0.56M0.73M1.08M0.45M-0.37M-0.05M-0.19M-1.42M-2.99M-2.91M0.23M
Cash from OperationsCash from Ops. -5.24M40.67M-5.38M-10.70M-7.98M-8.50M-6.17M-10.20M-14.41M-15.66M-12.20M-13.04M-16.27M-11.50M
Investing Activities
Capital ExpendituresCapex 0.05M0.03M0.02M0.31M0.15M0.12M0.08M0.17M0.05M0.04M0.10M0.04M0.31M0.01M
Change in Property, Plant and EquipmentChange in PP&E -0.05M-0.03M-0.02M-0.31M-0.15M-0.12M-0.08M-0.17M-0.05M-0.04M-0.10M-0.04M-0.31M-0.01M
Purchase of InvestmentsInvestments Purchased 9.22M58.58M52.08M22.00M30.64M69.01M72.41M54.35M33.69M25.44M18.64M84.73M97.12M45.79M
Sale and Maturity of InvestmentsInvestments Sold 18.62M14.15M12.60M31.34M39.52M30.23M42.28M45.13M48.65M39.37M33.68M37.32M58.12M50.65M
Cash from Investing ActivitiesCash from Investing 9.36M-44.46M-39.50M9.03M8.73M-38.90M-30.18M-9.39M14.92M13.88M14.94M-47.45M-39.31M4.85M
Financing Activities
Debt Issuance and Repayment
Long-Term Debt RepaymentsLT Debt Repayment 0.63M3.13M
Non-Current Debt -0.63M-3.13M
Net Debt Issuances and RepaymentsNet Debt Issuance -0.63M-3.13M
Change in Capital Stock
Common Stock IssuedStock Issued 0.01M0.02M0.08M0.05M0.12M108.22M-108.20M0.64M0.02M0.27M0.17M0.22M0.20M1.25M
Net Shares Issued and RepurchasedNet Shares Issued 0.01M0.02M0.08M0.05M0.12M108.22M-108.20M0.64M0.02M0.27M0.17M0.22M0.20M1.25M
Net Preferred Shares Issued and RepurchasedNet Pref. Shares Issued 10.24M
Net Equity Issued and RepurchasedNet Equity Issued 0.01M0.02M10.33M0.05M0.12M108.22M-108.20M0.64M0.02M0.27M0.17M0.22M0.20M1.25M
Other financing activitiesOther financing -0.14M0.14M-0.18M-0.08M-0.07M-0.05M
Cash from Financing ActivitiesCash from Financing -0.62M46.79M10.33M-0.32M-0.02M108.36M0.01M0.64M0.02M0.09M19.11M93.47M0.13M1.20M
Additional items
Change in Cash 3.49M43.01M-34.55M-2.00M0.74M60.97M-36.34M-18.95M0.53M-1.69M21.85M32.97M-55.45M-5.45M
Ending Cash Balance 9.06M52.07M17.52M15.53M16.26M77.23M40.89M21.94M22.47M20.78M42.63M75.60M20.16M14.71M
Free Cash FlowFCF -5.30M40.64M-5.40M-11.01M-8.12M-8.62M-6.25M-10.37M-14.46M-15.71M-12.30M-13.08M-16.58M-11.51M
Net Cash FlowNCF 3.49M43.01M-34.55M-2.00M0.74M60.97M-36.34M-18.95M0.53M-1.69M21.85M32.97M-55.45M-5.45M

Contineum Therapeutics Cash Flow Statement API

Pull Contineum Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=CTNM&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY